DE69714011T2 - Die erzeugung einer immunantwort gegen erwünschte determinanten - Google Patents

Die erzeugung einer immunantwort gegen erwünschte determinanten

Info

Publication number
DE69714011T2
DE69714011T2 DE69714011T DE69714011T DE69714011T2 DE 69714011 T2 DE69714011 T2 DE 69714011T2 DE 69714011 T DE69714011 T DE 69714011T DE 69714011 T DE69714011 T DE 69714011T DE 69714011 T2 DE69714011 T2 DE 69714011T2
Authority
DE
Germany
Prior art keywords
immune response
generation
determinants
desired determinants
provides compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69714011T
Other languages
English (en)
Other versions
DE69714011D1 (de
Inventor
L Alexander
Shawn Defrees
Alessandro Sette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of DE69714011D1 publication Critical patent/DE69714011D1/de
Application granted granted Critical
Publication of DE69714011T2 publication Critical patent/DE69714011T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Control Of High-Frequency Heating Circuits (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69714011T 1996-01-24 1997-01-23 Die erzeugung einer immunantwort gegen erwünschte determinanten Expired - Lifetime DE69714011T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1051096P 1996-01-24 1996-01-24
PCT/US1997/001041 WO1997026784A1 (en) 1996-01-24 1997-01-23 Induction of immune response against desired determinants

Publications (2)

Publication Number Publication Date
DE69714011D1 DE69714011D1 (de) 2002-08-22
DE69714011T2 true DE69714011T2 (de) 2003-02-27

Family

ID=21746084

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69714011T Expired - Lifetime DE69714011T2 (de) 1996-01-24 1997-01-23 Die erzeugung einer immunantwort gegen erwünschte determinanten

Country Status (12)

Country Link
EP (1) EP0876398B1 (de)
JP (1) JP4063879B2 (de)
CN (1) CN1214051A (de)
AT (1) ATE220687T1 (de)
AU (1) AU1582797A (de)
BR (1) BR9710404A (de)
CA (1) CA2242878C (de)
DE (1) DE69714011T2 (de)
DK (1) DK0876398T3 (de)
ES (1) ES2177927T3 (de)
PT (1) PT876398E (de)
WO (1) WO1997026784A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528061B1 (en) * 1997-09-04 2003-03-04 Pasteur Institut Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
MXPA05006113A (es) * 2002-12-11 2005-09-30 Pharmexa As Epitopos sencillos objetivo.
US20080274129A1 (en) 2003-04-18 2008-11-06 Fikes John D Hla-A2 Tumor Associated Antigen Peptides and Compositions
ES2310072B1 (es) 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
WO2009025777A1 (en) * 2007-08-17 2009-02-26 University Of Maryland Carbohydrate functionalized catanionic surfactant vesicles for drug delivery
JP5792630B2 (ja) * 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
US10588952B2 (en) * 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
EP3028048B1 (de) 2013-07-31 2018-09-26 BioVentures, LLC Zusammensetzungen zur behandlung und prävention von krebs durch anzielung von mit tumoren assoziierten kohlehydrat-antigenen
WO2015143126A1 (en) * 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
CN107141355B (zh) * 2017-05-31 2021-05-14 中国人民解放军第四军医大学 一种htnv抗原表位线性串联多肽及表位肽-复合物四聚体和应用
CN109991422A (zh) * 2017-12-29 2019-07-09 复旦大学 基于特异抗血清的棕榈酰化修饰蛋白质的检测方法
EP4149531A1 (de) 2020-05-11 2023-03-22 Ose Immunotherapeutics Impfstoff gegen sars-cov virus
KR102261457B1 (ko) * 2020-07-22 2021-06-09 (주)쓰리에이치바이오 면역 치료제용 펩타이드
CA3189004A1 (en) * 2020-07-22 2022-01-27 3H Bio. Co., Ltd. A peptide used for immunotherapeutics
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435292D1 (de) * 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
PT735893E (pt) * 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária

Also Published As

Publication number Publication date
DK0876398T3 (da) 2002-08-12
BR9710404A (pt) 1999-08-17
DE69714011D1 (de) 2002-08-22
ATE220687T1 (de) 2002-08-15
CA2242878A1 (en) 1997-07-31
ES2177927T3 (es) 2002-12-16
EP0876398B1 (de) 2002-07-17
JP2000504328A (ja) 2000-04-11
PT876398E (pt) 2002-12-31
CA2242878C (en) 2010-06-22
CN1214051A (zh) 1999-04-14
AU1582797A (en) 1997-08-20
EP0876398A1 (de) 1998-11-11
JP4063879B2 (ja) 2008-03-19
WO1997026784A1 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
DE69714011T2 (de) Die erzeugung einer immunantwort gegen erwünschte determinanten
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
DK0814836T3 (da) Vaccineadjuvanser
CY1108074T1 (el) Ανοσολογικες μεθοδοι για τη ρυθμιση της μυοστατινης σε σπονδυλωτα
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
ATE397005T1 (de) Sialyl-lewisa und sialyl-lewisx epitope analoge
EP1594536A4 (de) Adjuvante influenza-vakzine
EA199900069A1 (ru) Вакцинная композиция против малярии
NO964238D0 (no) Halofantrin-fri-base for behandling av malaria og blandinger
DE60136563D1 (de) Salmonella vakzine
HK1041219B (zh) 粘膜遞送系統
DK0787135T3 (da) Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh
DK1037642T3 (da) Modificerede polysaccharider med ændret biologisk genkendelse
FR2715304B1 (fr) Vaccin anti-allergique.
ATE210989T1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
BG105372A (en) Immunogenic liposome compositions
DK0858345T3 (da) Anvendelse af muteiner af vildtypecytokiner som immunogener
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
EP1555316A3 (de) Antigenbibliothek Immunisierung
UA36540A (uk) Спосіб проведення кліматооздоровчих процедур з використанням галотерапії та установка для його здійснення
UA36485A (uk) Спосіб лікування генералізованого пародонтиту
HUP9800094A2 (hu) Nem patogén mutáns E. coli törzsek, előállításuk és alkalmazásuk

Legal Events

Date Code Title Description
8364 No opposition during term of opposition